Premium
Optimal DAPT duration: Each in their own time
Author(s) -
Hillegass William B.,
Brott Brigitta C.
Publication year - 2014
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.25737
Subject(s) - medicine , percutaneous coronary intervention , clopidogrel , randomized controlled trial , cardiology , duration (music) , drug eluting stent , adverse effect , aspirin , myocardial infarction , art , literature
Key Points Meta‐analysis of randomized trials shows no significant difference in major adverse cardiovascular events between shorter (3–6 months) and longer (12–24 months) durations of clopidogrel‐based dual antiplatelet therapy (DAPT) after drug eluting stent (DES) implantation. Shorter durations (6 months) of DAPT should be considered in lower risk patients undergoing DES implantation in current practice. Further research should define the optimal agents and duration of DAPT after percutaneous coronary intervention based on patient specific factors.